Neurogenesis—the generation of new neurons from neural stem cells—occurs primarily in two brain regions in adults: the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus. Dysfunction in neurogenesis is increasingly recognized as a common feature across neurodegenerative diseases, though the patterns and consequences differ significantly between conditions.
| Feature |
Alzheimer's Disease |
Parkinson's Disease |
ALS |
Frontotemporal Dementia |
Huntington's Disease |
| Primary affected region |
Dentate gyrus (SGZ) |
SVZ, olfactory bulb |
Spinal cord SVZ |
Frontal/temporal cortex |
Striatum, SVZ |
| Neurogenesis change |
Severely reduced ↓↓↓ |
Moderately reduced ↓↓ |
Variable ↓ |
Reduced ↓↓ |
Severely reduced ↓↓↓ |
| NSC marker expression |
Nestin, Sox2 ↓ |
Nestin, Sox2 ↓ |
Nestin altered |
TBR2 ↓ |
Nestin, Sox2 ↓↓ |
| Neuroinflammation role |
High (IL-1β, TNF-α) |
Moderate |
High (microglia) |
Moderate-High |
Very High |
| Therapeutic targeting |
Active research |
Early stages |
Limited |
Very limited |
Active research |
In AD, neurogenesis dysfunction occurs early and progresses throughout the disease:
- Hippocampal impairment: Adult neurogenesis in the dentate gyrus is significantly reduced, with decreased proliferation of neural progenitor cells (NPCs)
- Beta-amyloid effects: Aβ oligomers directly inhibit neurogenesis through:
- Disruption of Wnt/β-catenin signaling
- Increased oxidative stress in the neurogenic niche
- Inflammation-mediated inhibition
- Tau pathology effects: Hyperphosphorylated tau accumulates in NPCs, disrupting their function
- Evidence: Post-mortem studies show 50-80% reduction in doublecortin-positive new neurons in AD hippocampus
Key references:
PD shows moderate neurogenesis impairment:
- Olfactory bulb involvement: Reduced olfactory neurogenesis contributes to anosmia
- Subventricular zone: Reduced proliferation in the SVZ
- Dopaminergic modulation: Loss of dopaminergic inhibition affects neurogenic niches
- Alpha-synuclein effects: Toxic aggregation interferes with NSC function
- Therapeutic potential: Exercise and GDNF may promote neurogenesis
ALS shows unique patterns:
- Spinal cord SVZ: Neural stem cells in the spinal cord show early dysfunction
- Motor neuron replacement: Attempts to replace lost motor neurons via neurogenesis
- Glial interactions: Astrocyte dysfunction affects neurogenic niche
- Limited regeneration: Unlike brain regions, spinal cord has very limited neurogenesis capacity
FTD involves cortical neurogenesis:
- TBR2 dysfunction: Loss of intermediate progenitor cells (TBR2+)
- Frontal cortex: Reduced neurogenesis in cortical regions
- Tau pathology: 4R-tau affects neural stem cells differently than 3R-tau
- Overlaps with AD: Some FTD subtypes show similar hippocampal impairment
HD shows the most severe neurogenesis impairment:
- Striatal dysfunction: Mutant huntingtin directly affects NSCs in the SVZ
- Neuronal loss: Severe reduction in neurogenesis contributes to striatal atrophy
- BDNF deficiency: Reduced neurotrophic support impairs neurogenesis
- Therapeutic target: Enhancing neurogenesis is a key HD therapeutic strategy
All neurodegenerative diseases show increased pro-inflammatory cytokines that suppress neurogenesis:
| Cytokine |
Effect on Neurogenesis |
Primary Source |
| IL-1β |
Strong inhibition |
Activated microglia |
| TNF-α |
Inhibition |
Microglia, astrocytes |
| IL-6 |
Moderate inhibition |
Astrocytes |
| IFN-γ |
Variable |
T-cells, microglia |
Reactive oxygen species (ROS) accumulate in neurogenic niches:
- Mitochondrial dysfunction reduces NPC function
- Antioxidant systems (GSH, SOD) are compromised
- DNA damage accumulates in NSCs
Growth factors critical for neurogenesis are reduced:
- BDNF: Reduced in AD, PD, HD
- GDNF: Reduced in PD
- IGF-1: Reduced across all conditions
- VEGF: Impaired vascular support
| Approach |
Disease Focus |
Stage |
| Exercise/Enriched Environment |
AD, PD |
Clinical |
| BDNF mimetics |
AD, HD |
Preclinical |
| NSC transplantation |
PD, ALS |
Early clinical |
| Small molecule enhancers |
Multiple |
Preclinical |
| Gene therapy (GDNF) |
PD |
Clinical |
- Wnt/β-catenin signaling: Enhance NSC proliferation
- Notch signaling: Promote NSC maintenance
- cAMP/CREB pathway: Increase neuronal differentiation
- Neuroinflammation reduction: Anti-inflammatory approaches
Neurogenesis dysfunction is a common feature across neurodegenerative diseases, though the severity, location, and mechanisms differ significantly. Understanding these differences and similarities provides opportunities for both disease-specific and cross-disease therapeutic approaches.